Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Metastatic
Does the lack of survival data with palbociclib in metastatic breast cancer make you lean towards using abemaciclib or ribociclib?
Related Questions
Would you consider using trastuzumab deruxtecan in a patient with progressive HR+ breast cancer that is HER2 2+ with prior history of cell cycle inhibitor related pneumonitis?
Would you use elacestrant in a patient with an ESR1-AKAP12 fusion?
How reliable is the liquid biopsy on patients with progressing HER2 positive breast cancer with negative HER2 on liquid testing?
In which scenarios do you stage breast cancer using CT and nuclear bone scans versus PET-CT?
What factors do you use to decide between trastuzumab-deruxtecan and sacituzumab govitecan in HER2-low metastatic breast cancer?
Are there any scenarios you would use CDK 4/6i to treat HR-positive HER2-positive breast cancer in combination with anti-HER2 agents?
What disease characteristics will guide your choice of alpelisib plus fulvestrant (per SOLAR-1) versus capivasertib plus fulvestrant (per CAPItello-291) in Pik3ca mutated advanced ER+/HER2- breast cancer after progression on 1L ET regimen, given both are now approved in this population?
Is there a role of adding hormonal therapy to fam-trastuzumab deruxtecan in patients with metastatic ER/PR+ HER2 low breast cancer after progressing on aromatase inhibitor and CDK4/6i?
How do you treat metastatic breast cancer which is HR positive, Her2 negative with PIK3CA+ and high tumor mutational burden (>10) who progressed after prior ET+CDK 4/6 and PIK3CA inhibitor therapy?
In metastatic hormone receptor positive breast cancer, would you consider combination exemestane and CDK4/6 inhibitor if letrozole and anastrazole are not tolerated?
